Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Addition of Pembrolizumab Upon Progression on Enzalutamide in Men With mCRPC

NCT02312557 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT02312557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02312557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Addition of Pembrolizumab Upon Progression on Enzalutamide in Men With mCRPC
Lead sponsor
OHSU Knight Cancer Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 18, 2014
Completion date
October 31, 2026
Enrollment
58 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate carcinoma, hormone-resistant prostate cancer, psa progression, recurrent prostate carcinoma, stage iv prostate adenocarcinoma cancer ajcc v8